NEW YORK (GenomeWeb News) – Invitrogen announced today that it will work with Maryland-based biotechnology company Lentigen to develop and market products and services for gene over-expression based on Lentigen’s lentiviral gene delivery technology and Invitrogen’s human gene collections and cloning and gene synthesis technologies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.